Cargando…

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

AIMS/HYPOTHESIS: Using the Echantillon Généraliste de Bénéficiaires: random 1/97 permanent sample of the French national healthcare insurance system database (EGB), we investigated whether, as previously suspected, the risk of cancer in insulin glargine (A21Gly,B31Arg,B32Arg human insulin) users is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blin, P., Lassalle, R., Dureau-Pournin, C., Ambrosino, B., Bernard, M. A., Abouelfath, A., Gin, H., Le Jeunne, C., Pariente, A., Droz, C., Moore, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268990/ https://www.ncbi.nlm.nih.gov/pubmed/22222504 http://dx.doi.org/10.1007/s00125-011-2429-5

Ejemplares similares

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC
por: Blin, Patrick, et al.
Publicado: (2015)

Secondary prevention of acute coronary syndrome with antiplatelet agents in real life: A high-dimensional propensity score matched cohort study in the French National claims database
por: Blin, Patrick, et al.
Publicado: (2020)

Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database
por: Blin, Patrick, et al.
Publicado: (2021)

Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation: A Population-Based New Users High-Dimensional Propensity Score Matched Cohorts Study
por: Blin, Patrick, et al.
Publicado: (2019)

Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis
por: Aubin, Henri-Jean, et al.
Publicado: (2021)

Corrigendum to: Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis
por: Aubin, Henri-Jean, et al.
Publicado: (2021)

Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database
por: Billioti de Gage, Sophie, et al.
Publicado: (2018)

Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?: A French nationwide cohort study based on national administrative databases
por: Fagot, Jean-Paul, et al.
Publicado: (2013)

Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data
por: Thurin, Nicolas H., et al.
Publicado: (2021)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Real‐World Effectiveness of Osteoporosis Medications in France: A Nationwide Cohort Study
por: Bosco‐Lévy, Pauline, et al.
Publicado: (2023)

Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases
por: Lassalle, Marion, et al.
Publicado: (2018)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin Glargine Controversy: A Tribute to the Editorial Team at Diabetologia
por: Butler, Peter C.
Publicado: (2009)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Linking disease registries and nationwide healthcare administrative databases: the French renal epidemiology and information network (REIN) insight
por: Raffray, Maxime, et al.
Publicado: (2020)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

rDNA insulin glargine U300 – a critical appraisal
por: Wang, Fei, et al.
Publicado: (2016)

Prolonged Hypoglycemic Effect Due to Intentional Massive Insulin Glargine Overdose
por: Gill, Kirit S, et al.
Publicado: (2021)

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
por: Murphy, Lisa A, et al.
Publicado: (2016)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
por: Rodbard, H W, et al.
Publicado: (2013)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_91sie95krolm7uu55tauq6t998